S_smary We have investigated the effects of H+-ATPase inhibitors, bafilomycin Al and 7-chloro-4-nitrobenz-2-oxa-1,3 diazole (NBD), and the Golgi inhibitor, brefeldin A, on daunorubicin accumulation and doxorubicin intracellular distribution in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23 R. This cell line overexpresses a 190 kDa protein which is probably the product of the MRP gene and shows an anthracycline accumulation defect and a drastically altered intracellular anthracycline distribution from the parental cell line COR-L23/P. We found that all three agents could selectively increase the cellular accumulation of daunorubicin in resistant cells. However, these effects were only seen at doses of the modifiers which were equal to or greater than the IC50 of the modifier alone. Effects of the modifiers on the intracellular distribution of doxorubicin fluorescence could, however, be seen at doses lower than those required to produce significant effects on daunorubicin accumulation. However, when used in a continuous MTT chemosensitivity assay none of the agents, used at maximum non-toxic doses, was able to sensitise COR-L23/R cells to doxorubicin or to colchicine. Although these lead compounds are unlikely to be useful as clinical modifiers, development of more selective analogues may prove useful in the modification of non-P-glycoprotein-mediated multidrug resistance.
Acquired resistance of tumours to a group of structurally and functionally unrelated cytotoxic drugs (multidrug resistance, MDR) can be modelled in vitro by exposing tumour cell lines to one of the group of drugs. Overexpression of a 170 kDa glycoprotein (P-glycoprotein, Pgp), acting as an efflux pump in the plasma membrane, has been demonstrated as a principal mechanism of MDR in many such cell lines (Juranka et al., 1989) . However, some MDR cell lines efflux MDR drugs but do not overexpress the Pgp pump. An example is the human large-cell lung carcinoma line COR-L23/R, developed by stepwise increases in exposure to doxorubicin (Twentyman et al., 1986) , and resistant to doxorubicin, daunorubicin, colchicine, (Coley et al., 1991) . This cell line exhibits decreased intracellular drug accumulation compared with the parental line, with no detectable overexpression of Pgp or of mRNA from the encoding mdrl gene (Barrand et al., 1990; Reeve et al., 1990) . A number of other such cell lines with similar patterns of cross-resistance but lacking Pgp have also been described (McGrath & Center, 1987; Mirski et al., 1987; Zijlstra et al., 1987; Kuiper et al.. 1990) .
A series of antisera to synthetic peptides from the deduced sequence of Pgp were used to study a non-Pgp MDR human leukaemia cell line (HL60,Adr) (Marquardt et al., 1990) . One of the antisera detected the presence of a 190 kDa membrane protein in the resistant cells but not in the parental cells from which they were derived. This antiserum (ASP-14) was also used to identify a protein of the same size in our COR-L23/R non-Pgp MDR line (Barrand et al., 1993) . It now appears probable that the 190 kDa protein band detected by antiserum ASP14 (and also by our own similar antiserum, CRA-1) includes the product of the MRP gene, isolated and sequenced from a non-Pgp-mediated human small-cell lung cancer MDR subline H69/AR (Cole et al., 1992 are highly effective modifiers of drug resistance in MDR cells having overexpression of Pgp (Ford & Hait. 1990 (Marquardt & Center, 1992; Barrand et al., 1993; Coley et al., 1993) . Whereas intracellular fluorescence of drug is mainly confined to the nucleus of COR-L23/P parental cells, the most intensive fluorescence in COR-L23, R resistant cells is seen in groups of perinuclear vesicles. Daunorubicin initially enters the nucleus of HL60/Adr cells, and redistribution follows with efflux of drug from the nucleus of resistant cells. Marquardt et al. (1990) have localised the 190 kDa protein in HL60/Adr to the endoplasmic reticulum. They have proposed a pathway of drug extrusion which involves the concentration of anthracyclines into cytoplasmic vesicles followed by an exocytotic process transporting the drug to the exterior of the cell. This proposal is corroborated by evidence that vacuolar H+-ATPase plays an important part in the pathway of drug efflux from these cells (Marquardt & Center, 199 1).
We have, therefore, investigated the effect on drug accumulation in our COR-L23,/R cell line of the inhibitors of vacuolar H+-ATPases, bafilomycin Al and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD), which were reported to restore drug accumulation in the HL60/Adr cells used in the above-mentioned study (Marquardt & Center, 1991) . We have also examined the effects of the fungal antibiotic, brefeldin A, which has been identified as an inhibitor of protein recycling from the endoplasmic reticulum into the Golgi body (Lippincott-Schwartz et al.. 1989; Marquardt & Center, 1992) . The effects of these compounds on the growth, intracellular anthracycline distribution and accumulation and chemosensitisation in COR-L23/P and COR-L23/R cell lines are the focus of this study.
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Materals and medKods
Cell lines
The large cell lung carcinoma cell line COR-L23/P (BaillieJohnson et al., 1985) and MDR subine COR-L23/R were derived in this laboratory. COR-L23/R was made drug resistant by in vitro exposure to increasing doses of doxorubicin (Twentyman et al., 1986) 
Drug response
The MTT assay used to determine drug sensitivity was based on that described by Mosmann (1983) and modified in this laboratory (Twentyman & Luscombe, 1987 Wbereas drug accumulation studies were carried out with daunorubicin because of the ready availability of radiolabelled compound at a reasonable price, we used doxorubicin for confocal studies of intracellular distribution. The reason for this choice is that measurement of nuclear/cytoplasmic fluorescent ratios is facilitated by a better-defined nucleus for doxorubicin than for daunorubicin and because differences between parent and resistant cells are greater for the former anthracycline.
Results
Toxicity of modfiers alone MiT assays were carried out in order to assess the toxicity of brefeldin A, bafilomycin Al and NBD in the COR-L23/P and COR-L23/R cell lines. Effects following different exposure conditions were investigated, and the IC50 values are shown in Table I . We used both short-term (i.e. 2 h) areas of the cytoplasm, with low levels in the nucleus and other cytoplasmnic areas as previously described (Barrand et al., 1993; Coley et al., 1993) . A shift of drug from cytoplasmic to nuclear regions was seen in the resistant cells when treated with brefeldin A, (18 tiM) ( Figure 2c ) and bafilomycin A, (411M) (Figure 2d ), resulting in a distribution closer to that in the parental control (Figure 2a ) than the resistant control ( Figure 2b ). Whole-cxll drug fluorescence was also brighter in COR-L23/R when treated with brefeldin A (18 gM) (Figure 2c) 190 kDa protein disinct from Pgp. Intracellular drug distribution was studied for HL60/AR (a imilar subline to HL60/ Adr) and COR-L23/R using laser-assisted confocal microscopy, and both were found to accumulate anthracyclines in cytoplamic vesicles (Hindenburg et al., 1989; Barrand et al., 1993; Coley et al., 1992) . Marquardt and Center (1992) suggested a mechanism for drug extrusion from their non-Pgp HL60/Adr cell line which involves intracellular vesicular transport. With this mechanism in mind, we have investigated the effects of compounds which interrupt vesicular transport on the drug distribution within resistant and sensitive cells. Both bafilomycin Al and NBD have been shown to increase whole-cell drug accumulation in the HL60/ Adr cell line (Marquandt & Center, 1991) , whereas the Golgi recycling inhibitor brefeldin A did not alter drug accumulation in the same cell line (Marquardt & Center, 1992) .
Toxicity of brefeldin A to COR-L23/P and COR-L23/R cell lines had been investigated previously and inhibited drug efflux in HL60/Vinc and HL60/Adr. However, toxicity data for these compounds in the HL60 cell lines were not presented and it is therefore impossible to interpret these data in mechanistic terms.
In our study both the Golgi inhibitor brefeldin A and the H+-ATPase inhibitors bafilomycin A1 and NBD increased, in a dose-dependent manner, the [HJdaunorubicin accumulation in COR-L23/R at doses which had little effect on the accumulation in the drug-sensitive parental line COR-L23/P. However, only the highest dose (100IM) of NBD brought the drug content in the resistant cell line COR-L23/R to levels equal to those in the parental line. These increases were, however, statistically significant only for brefeldin A at 36 lM (although close to signifiance at 18 gM) in COR-L23/ R, bafilomycin Al in COR-L23/R at I0LM but not at 41M
and NBD for both the parent and resistant lines at 100 pM.
Effects of increasig drug accumulation in restant ines by both brefeldin A and bafilomycin Al were therefore only seen at doses close to the ICQ valus for these agents (i.e. 38.9 M and 3.9 m re ). Similarly, 100 JM NBD is many times higher than the IC50 for this agent alone. It is therefore impossible to distinguish from these data between a specific effect on the drug efflux mechanism operative in COR-L23/R and circumvention of this mechanism by nonspecific membrane damage.
The assessent of whole-cell drug accumulation may not reveal changes which occur on an intracellular level in drug distributon between different compartments in parental and resistant cells. Following treatment with these compounds, the visualsation of intracellular drug fluorescence in COR-L23/P and COR-L23/R by laser-scan confocal microscopy allows the shift of doxorubicin distribution to be observed. Our results show that each of the compounds studied can modify the distribution in the resistant cells towards that seen in parental cells, although the greatest effects on intracellular distribution are again only seen at doses of modifiers which are themselves toxic.
Quantitation of intracellular drug fluorescence can be achieved by image analysis in conjunction with confocal microscopy. Using such analysis we have found that brefeldin A (18 JM) significntly shifts doxorubicin fluorescence from the cytoplasm to the nucleus in the reistant cell line, with no signiit changes to the parental line. Bafilomycin Al produced changes in intracellular doxorubicin distribution at a dose which did not greatly increase daunorubicin cellular accumulation. However, distribution was also sigificntly altered in the parent lne by this agent. A dose of 10I1M NBD signifintly altered distribution in the reistant but not the parental line. It is possible, therefore, to observe shifts of doxorubicin fluorescence within the cell, towards the nucleus, at modifer doses which do not produce dramatic changes in cellular drug accumulation of daunorubicin. It seems likely therefore that the measurement of effects on intracellular drug distribution will constitute an important aspect in the development of modifirs for non-Pgp MDR.
Despite the activity of these compounds as modifiers of drug distribution, the cytotoxic concentrations required to achieve any effect only allowed for investigation of sensitisation under these conditions with brefeldin A, where only minimal selective sensitisation was observed. There was no sensitisation at the doses used for continuous exposure experiments as would be expected for a potent modifier. The compounds in this study were chosen as potential modifies of non-Pgp MDR with alternative methods of action to the traditional Pgp-binding compounds. Marquardt and Center (1991) postulated a H+-ATPase inhibitory effect of bafilomycin A1 and NBD, which reversed the accumulation deficit in both the Pgp-and non-Pgp-containing cell lines in their study. Any effect of brefeldin A may be related to its function as a Golgi inhibitor (Lippincot-Schwartz et al., 1989) . However, the compounds were no better than the standard Pgp chemosensitisers cyclosporin A, PSC-833 and verapamil (Barfand et al., 1993) ; in fact, verapamil is the most active of these agents in reversing the accumulation deficit. Clearly, none of the compounds reported so far as non-Pgp modifiers shows the large differential effects that are seen when compounds such as cyclosponn A and PSC-833 are used to sensitise Pgp-expressing cell lines.
The data which we have presented indicate that the three compounds which we have studied are unlikely to be useful as potential clinial modifiers. The results, however, are sufficiently positive that further investigation of related compounds with possibly improved therapeutic indices may be worthwhile. 
